Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Progenics' (PGNX) Relistor Setback Only a Speedbump - Jefferies
April 5, 2016 9:34 AM EDTJefferies analyst, Gena Wang, sees the FDA extension for Progenics Pharmaceuticals' (NASDAQ: PGNX) oral Relistor as a timing setback only. No change to Buy rating or $9 PT.
The FDA extended the PDUFA by 3mon (to July 19) for oral Relistor in opioidinduced constipation in... More
Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
April 4, 2016 1:23 PM EDTNeedham & Company analyst Chad Messer has come out to defend Progenics Pharmaceuticals (NASDAQ: PGNX), which is down 6.5% after the FDA extended oral Relistor PDFUA by 3 months to July 19th. The FDA made the extension in order to review responses by Valeant to recent... More
